Halozyme says EPO revokes Janssen co-formulation patent; reaffirms 2023 guidance

HALOZYME THERAPEUTICS, INC.

EPO Opposition Division revoked Janssen's European Patent EP3370770B1 for DARZALEX SC co-formulation.
Halozyme reiterates 2023 revenue guidance of $815M-$845M and royalty revenue of $445M-$455M.
Affirms total royalty revenue projection of ~$1B by 2027 and thereafter to at least 2030.
License with Janssen: co-formulation patents do not extend royalty step-down beyond 2024 in EU, 2027 in US.
Written decision expected in months; if appeal filed, patent remains in force until final decision.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.